# Public Health Wales CDSC Weekly Influenza & Acute Respiratory Infection Surveillance Report



Wednesday 16th November 2022 (covering week 45 2022)

Current level of influenza activity: Low Influenza activity trend: Increasing

Confirmed influenza cases since 2022 week 40: 657 (261 influenza A(H3N2), 159 influenza A(H1N1)pdm09, 224

influenza A(not subtyped) and 13 influenza B)


## **Key points - Wales**

Influenza is beginning to circulate in Wales and confirmed cases of RSV remain at very high intensity levels. During Week 45 (ending 13/11/2022) there were 140 cases of influenza (an increase from the previous week). COVID-19 cases continue to be detected in symptomatic patients in hospitals and in the community. RSV incidence in children under 5 years of age is currently at levels that would indicate very high levels of activity (compared to the 10 seasons leading up to 2020). Rhinovirus, RSV and adenovirus are the most commonly detected cause of non-COVID-19 Acute Respiratory Infection (ARI).

- The Sentinel GP consultation rate for influenza-like illness (ILI) in Wales during week 45, was 7.0 consultations per 100,000 practice population (Table 1). This is an increase compared to the previous week (6.3 consultations per 100,000) but remains below the baseline threshold for seasonal influenza activity (11.0 per 100,000 practice population) (Figure 1). Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic.
- The Sentinel GP consultation rate for Acute Respiratory Infections (ARI) was 213.6 per 100,000 practice population during Week 45, this is a decrease compared to the previous week (227.9 per 100,000) (Table 2 and Figure 3). Weekly consultations for both Lower Respiratory Tract Infections and Upper Respiratory Tract Infections decreased compared to the previous week.
- The percentage of calls to **NHS Direct Wales** which were 'influenza-related' (cold/flu, cough, fever, headache and sore throat) during Week 45 increased to 20.7% (Figure 9).
- During Week 45, 1,430 specimens received multiplex respiratory panel testing mainly from patients attending hospitals. These results do not include samples tested solely for SARS-CoV-2. There were 100 samples positive for influenza (7.0% positivity) of which 39 were A(H1N1), 52 were A(H3N2), seven were A(not typed), and two were influenza B. There were 206 RSV, 55 parainfluenza, 251 rhinovirus, 36 human metapneumonovirus, 98 adenovirus, 39 enterovirus, 15 seasonal coronavirus and 137 SARS-CoV2 positive samples in Week 45 (Figure 5). Additionally, 1,104 samples from patients were tested for influenza, RSV and SARS-CoV2 only, many of these tests may be associated with screening activities rather than diagnostic testing for patients presenting with ARI symptoms. Of these 1,104 samples, 37 were positive for influenza A and one for influenza B, 31 were positive for RSV and 86 were positive for SARS-CoV2 (Figure 6). Ninety-three respiratory specimens were tested from patients in intensive care units (ICU) of which one was positive for influenza (Figure 7). For the latest COVID-19/SARS-CoV2 surveillance data please see the PHW daily dashboard
- There were 26 surveillance samples from patients with ILI collected by **sentinel GPs** during Week 45. Of the 26 samples, two samples tested positive for influenza A(H3N2), four for RSV, one for rhinovirus, one for parainfluenza, one for human metapneumovirus, three for enterovirus and two for SARS-CoV (as at 16/11/2022) (Figure 4).
- Confirmed RSV case incidence in children aged under 5 has further increased, and remains at very high intensity levels. In week 45 there were 91.4 confirmed cases per 100,000 in this age group (Figure 7). The provisional MEM threshold in Wales which predicts the start of the annual RSV season in children younger than five years is 6.3 confirmed cases per 100,000.
- During Week 45, 17 ARI outbreaks were reported to the Public Health Wales Health Protection team, 12 of them
  were reported as COVID-19 and five as influenza A. Sixteen of these ARI outbreaks were reported in residential
  care homes, and one was reported in a custodial setting.
- According to <u>EuroMoMo</u> analysis, all-cause deaths in Wales were not significantly in excess during week 45.

Figure 1. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (as of 13/11/2022).


# Respiratory infection activity in Wales



<sup>\*</sup> The Moving Epidemic Method (MEM) threshold calculated for Wales ILI consultation rates is 11.1 per 100,000. MEM thresholds used in this chart are based on influenza from 2010-11 to 2018-19 seasons. Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic.

\*\*Clinical consultations for ILI seasons are monitored from W40 to W40, the most recent data is presented in red.

Figure 2. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (week 48 1996 – week 45 2022).



<sup>\*</sup> Reporting changed to Audit+ surveillance system

Table 1. Age-specific consultations (per 100,000) for ILI in Welsh sentinel practices, week 40 – week 45 2022 (as of 13/11/2022).

Age						
group	40	41	42	43	44	45
< 1	0.0	0.0	0.0	0.0	0.0	0.0
1 - 4	0.0	0.0	13.6	6.8	6.8	7.3
5 - 14	0.0	2.3	4.5	2.2	2.2	2.4
15 - 24	4.3	2.3	0.0	0.0	6.5	2.3
25 - 34	5.8	2.0	2.0	9.7	5.8	8.3
35 - 44	7.7	4.0	5.8	11.5	15.4	16.5
45 - 64	2.8	4.8	3.7	4.6	3.7	7.8
65 - 74	0.0	2.3	4.4	2.2	4.3	6.9
75+	4.5	0.0	2.3	2.3	9.0	2.4
Total	3.4	2.8	3.7	4.9	6.3	7.0

Table 2. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 40 – week 45 2022 (as of 13/11/2022).

Age						
group	40	41	42	43	44	45
< 1	1048.7	1249.6	1209.7	1330.9	1616.4	1974.6
1 - 4	886.5	902.9	1043.8	1076.2	1143.6	962.52
5 - 14	255.3	265.7	302.7	333.63	230.65	304.82
15 - 24	173.8	160.1	146.7	180.24	206.08	179.6
25 - 34	193.5	136.9	179.4	170.05	171.9	155.52
35 - 44	191.0	162.3	176.5	207.52	178.53	191.59
45 - 64	163.0	178.0	155.0	162.98	162.08	134.92
65 - 74	160.2	145.9	107.0	164.55	175.33	142.21
75+	213.8	184.5	192.1	195.46	181.95	146.55
Total	219.6	210.0	214.6	235.4	227.9	213.6

Figure 3. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 1 – week 45 2022 (as of 13/11/2022).






Figure 4. Specimens submitted for virological testing by sentinel GPs as of 13/11/2022, by week of sample collection, week 45 2021 to week 45 2022.



<sup>\*</sup> Tested negative for influenza, adenovirus, rhinovirus, RSV, parainfluenza, mycoplasma, human metapneumovirus, enterovirus, bocavirus and coronaviruses. Samples which test positive for more than on pathogen will appear more than once in the chart.





This chart summarises respiratory panel test data and does not include data for patients tested SOLEY for SARS-CoV2. Combined data for tests carried out in Public Health Wales Microbiology: Cardiff laboratory, provided by Public Health Wales Microbiology Cardiff Specialist Virology Centre. This chart summarises individual test results, patients who are positive for multiple infections within a given week will appear multiple times. Samples which test positive for more than on pathogen will appear more than once in the chart.

Figure 6. Specimens from hospital patients submitted for RSV, Influenza and SARS-CoV2 testing only, as of 13/11/2022 by week of sample collection, week 45 2021 to week 45 2022.






Figure 7. Specimens submitted for virological testing for ICU patients, by week of sample collection, week 45 2021 to Week 45 2022.



This chart summarises respiratory panel test data and does not include data for patients tested SOLELY for SARS-CoV2. Samples which test positive for more than on pathogen will appear more than once in the chart.


Figure 8. RSV incidence rate per 100,000 population aged under five years, week 30 2018 to Week 45 2022.



<sup>\*</sup>RSV seasons are monitored from W30 to W29, the most recent data is presented in red

# **Calls to NHS Direct Wales**

Figure 9. Influenza related calls to NHS Direct Wales<sup>1</sup> (as a percentage of total calls) from week 45 2018 - Week 45 2022 (as of 13/11/2022).



<sup>&</sup>lt;sup>1</sup> Data supplied by Health Statistics and Analysis Unit, Welsh Government.

Flu related calls are the sum of calls recorded as 'cold/flu', 'cough', 'headache', 'fever' and 'sore throat'. Following changes to the NHS Direct calls system, including the start of the 111 pilot, there has been a change in the way in which denominator data are calculated for this chart, NHS Direct Wales now count the total number of nurse triaged calls (i.e. calls which could have symptom data recorded against them), note that 111 includes out-of-hours calls.

# **Influenza Vaccine Uptake in Wales**

Table 3. Uptake of influenza immunisations in GP Practice patients in Wales 2022/23 (as of 10/11/2022).

Influenza immunisation uptake in the 2022/23 season				
People aged 65y and older	61.9%			
People younger than 65y in a clinical risk group	29.5%			
Children aged two & three years	24.5%			

Uptake in other eligible groups will be available in the coming weeks.

The end of season report Influenza in Wales 2019/20 is available to download and contains a full breakdown of vaccination uptake amongst eligible groups.

Link to report: https://phw.nhs.wales/topics/immunisation-and-vaccines/fluvaccine/annual-influenza-surveillance-and-influenza-vaccination-uptake-reports/

# Influenza activity – UK and international summary

- As of week 44 community and syndromic influenza indicators remained low in the UK. GP ILI consultations
  decreased in Scotland to 3.6 per 100,000, and in Northern Ireland to 3.0 per 100,000 well below the baseline
  intensity threshold. The weekly ILI GP consultation rate in England reported through the RCGP system decreased
  to 3.5 per 100,000, below the MEM threshold for baseline activity (12.2 per 100,000).
- During week 44, 161 samples tested positive for influenza in England (including 14 A(H1N1)pdm09, 48 A(H3N2), 99 A(not subtyped) and six influenza B). Overall influenza positivity increased to 6.6%. UK summary data are available from the UKHSA Influenza and COVID-19 Surveillance Report.
- The WHO and the European Centre for Disease Prevention and Control (ECDC) reported its fifth weekly analysis of the season 2022-2023. During week 44, 18 countries reported baseline-intensity, 17 reported low-intensity, and one reported high-intensity (Malta). Nine out of 36 reporting countries reported no influenza activity across the region, 19 reported sporadic spread, three reported local spread (Bosnia and Herzegovina, Lithuainia and Malta), three reported regional spread (France, Germany and Ukraine), and two reported widespread activity (Portugal and United Kingdom (Scotland)). During week 44, 79 of 1,214 (7%) samples from patients presenting to all sentinel primary care centres with ILI or ARI symptoms were tested positive for influenza. This is an increase of 1% from the previous week, but remains below the threshold for epidemic activity (10%). Above-threshold positivity has been reported in Germany at 17%, Kazakhstan at 11%, and United Kingdom (Scotland) at 11%. Of sentinel specimens that tested positive for influenza for the season to date, 88% were influenza A (82% H3, 18% A(H1N1)pdm09) and 12% were influenza B. **Source:** Flu News Europe: http://www.flunewseurope.org/
- The WHO reported on 14/11/2022, based on data up to 30/10/2022, that globally, influenza activity remains low, although an increasing trend has been observed in the northern hemisphere.
- In the temperate zones of the southern hemisphere, overall influenza activity has now plateaued.
- In temperate South America, influenza detections continued to increase, of predominately A(H3N2) in Chile and Uruguay, and influenza B followed by A(H1N1)pdm09 in Argentina.
- In tropical South America, influenza detections remained low with A(H3N2) viruses predominating.
- In the Caribbean and Central American countries, influenza detections of predominantly A(H3N2) virus were reported but remained low, however influenza activity in Puerto Rico, Guatemala and Nicaragua was reportedly above levels expected for this time of year.
- In Western Africa, influenza activity remained low and stable with influenza B/Victoria detections increasing and A(H3N2) detections decreasing. In Northern and Middle Africa, no detections were reported. In Eastern Africa, influenza A and B detections decreased.
- In Southern Asia, influenza detections of predominately A(H3N2) viruses increased steeply mainly due to an increase in activity reported in Iran. Detections of A(H1N1)pdm09 and influenza B viruses were also reported. In South-East Asia, influenza activity decreased. In East Asia, influenza activity of predominantly influenza A(H3N2) continue to be reported. In Western Asia, influenza detections continued to increase in some countries of the Arab Peninsula. In Central Asia, high influenza activity was reported of predominantly influenza B viruses with widespread activity with positivity above 10% in Kazakhstan.
- In North America, influenza activity steeply increased. ILI activity in Canada increased to levels above the seasonal average for this time of year and ILI visits continue to surpass the baseline. Influenza A(H3N2) accounted for the majority of subtyped viruses.
- In Europe, overall influenza activity remained low but with an increasing trend. Influenza A viruses predominated among reported detections, A(H3N2) accounting for the majority of subtyped detections. RSV activity increased in the USA and Canada, with above average levels for this time of year in Canada. Source: WHO influenza update:https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-update
- Based on FluNet reporting (as of 14/11/2022), during the time period from 17/10/2022 30/10/2022, National Influenza Centres and other national influenza laboratories from 105 countries, areas or territories reported influenza surveillance data. The WHO Global Influenza Surveillance and Response System laboratories tested more than 229,940 specimens during that time period, of which 15,723 were positive for influenza viruses. 14,589 (92.8%) of those positive for influenza were typed as influenza A (of the subtyped influenza A viruses, 1,424 (21.2%) were influenza A(H1N1)pdm09 and 5,284 (78.8%) were influenza A(H3N2)) and 1,134 (7.2%) influenza B (of the 300 characterised influenza B viruses, all belonged to the B-Victoria lineage). Source: FluNet: <a href="https://www.who.int/tools/flunet">https://www.who.int/tools/flunet</a>

#### Update on influenza activity in North America

- The USA Centers for Disease Control and Prevention (CDC) report that there have been early increases in seasonal influenza activity in the United States during week 44 (ending 05/11/2022). Nationally, 13,178 (12.8%) out of 103,311 specimens have tested positive for influenza in week 44 in clinical laboratories nationwide, of these positives 13,086 (99.3%) were influenza A and 92 (0.7%) were influenza B. Further characterisation has been carried out on 8,824 specimens by public health laboratories, and 705 samples tested positive for influenza; 108 influenza A(H1N1)pdm09, 325 influenza A(H3N2), 267 influenza A(not subtyped) and five influenza B. Source: CDC Weekly US Influenza Surveillance Report: http://www.cdc.gov/flu/weekly/
- The Public Health Agency of Canada reported that during week 44, influenza activity increased steeply and has exceeded the seasonal positivity threshold. During week 44, 2,234 influenza detections were reported; 2,231 influenza A (predominantly A(H3N2) at 96%), and three influenza B. The percentage of ILI visits fell slightly to 1,2%.

**Source:** Public Health Agency of Canada: <a href="https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html">https://www.canada.ca/en/public-health/services/diseases/flu-influenza-surveillance/weekly-influenza-reports.html</a>

# Respiratory syncytial virus (RSV) in North America

The USA CDC reported an out of season increase in RSV activity, beginning in February 2022. This followed outof-season activity also reported during 2021. RSV positivity rate increased in the week beginning 05/11/2022.
 Source: CDC RSV national trends: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html

## **COVID-19 – UK and international summary**

- As of 09/11/2022, the new positive PCR episodes for the most recent 7-day reporting period was 11 per 100,000 population in Wales. There were 24 suspected COVID-19 deaths with a date of death in the most recent 7-day reporting period, reported to Public Health Wales. There were 29 COVID-19 death registrations in the last reporting period provided by ONS. Latest COVID-19 data from Public Health Wales is available from: <a href="https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/">https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/</a>
- The latest UKHSA COVID-19 data summary is available from: https://coronavirus.data.gov.uk/
- WHO situation updates on COVID-19 are available from: https://covid19.who.int/

## Middle East respiratory syndrome coronavirus (MERS-CoV) – latest update from WHO and ECDC

- On 28/04/2022 WHO reported an additional case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Oman, this follows on from two laboratory-confirmed cases (including 1 death) reported from Qatar between 22/03/2022 to 03/04/2022. Since the beginning of 2022 and as of 16/11/2022 there have been three reported cases of MERS-CoV. As of 15/05/2022, 2,591 laboratory confirmed cases of human infection with MERS-CoV, including 894 associated deaths, from across the globe have officially been reported to WHO since 2012. Source: WHO Global Alert and Response website: <a href="https://www.who.int/emergencies/disease-outbreak-news">https://www.who.int/emergencies/disease-outbreak-news</a>
- The majority of the MERS cases continue to be reported from Middle Eastern countries within the Arabian Peninsula, and specifically from Saudi Arabia. Rapid risk assessments of the situation from ECDC, which contain epidemiological updates and advice for travellers and healthcare workers, are available from: <a href="https://ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus">https://ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus</a>
- Further updates and advice for healthcare workers and travellers are available from WHO:
   <a href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</a> and from NaTHNaC:
   <a href="https://travelhealthpro.org.uk/news/237/mers-cov-update-travelhealthpro-country-pages">https://travelhealthpro.org.uk/news/237/mers-cov-update-travelhealthpro-country-pages</a>

# Human infection with avian influenza A(H7N9), China

- The latest WHO Influenza at Human-Animal Interface summary (31/08/2022 05/10/2022) reports that there have been no publicly available reports from China or other countries on influenza A(H7N9) in recent months. Since February 2013, a total of 1,568 laboratory-confirmed cases of human infection with avian influenza A(H7N9), including at least 616 deaths, have been reported to the global influenza programme: <a href="https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary">https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary</a>
- The risk of international spread of avian influenza A(H7N9) is considered to be low at present. However, it is
  important that clinicians are aware of the possibility of human infection with animal influenza, in persons presenting
  with severe acute respiratory disease, while travelling or soon after returning from an area where avian influenza
  is a concern. WHO Global Alert & Response updates: <a href="https://www.who.int/emergencies/disease-outbreak-news">https://www.who.int/emergencies/disease-outbreak-news</a>

#### Links:

Public Health Wales influenza surveillance webpage:

http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=25480

#### Public Health Wales COVID-19 data dashboard:

https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/

#### **GP Sentinel Surveillance of Infections Scheme:**

http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=27918

#### NICE influenza antiviral usage guidance:

http://www.nice.org.uk/Guidance/TA158

#### **England influenza and COVID-19 surveillance:**

https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2022-to-2023-season

## Scotland seasonal respiratory surveillance:

https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/weekly-national-seasonal-respiratory-report/

#### Northern Ireland influenza surveillance:

https://www.publichealth.hscni.net/directorate-public-health/health-protection/seasonal-influenza

#### **European Centre for Communicable Disease:**

http://ecdc.europa.eu/

#### **European influenza information:**

http://flunewseurope.org/

#### Advice on influenza immunisation

https://phw.nhs.wales/topics/immunisation-and-vaccines/fluvaccine/

## Advice on influenza immunisation (for intranet users)

Influenza (sharepoint.com)

For further information on this report, please email Public Health Wales using:

surveillance.requests@wales.nhs.uk